瑞舒伐他汀治疗急性自发性脑出血的临床疗效及保护作用研究  

Clinical efficacy and protective effects of rosuvastatin for patients with acute spontaneous intracerebral hemorrhage

作　　者：钟洁霞[1] 

机构地区：[1]广东省江门市人民医院药剂科,江门529000

出　　处：《北方药学》2015年第4期98-99,共2页Journal of North Pharmacy

摘　　要：目的:观察瑞舒伐他汀治疗急性自发性脑出血的临床疗效及其对血清氧自由基丙二醛(MDA)、白介素-1β(IL-1β)和肿瘤坏死因子(TNF-α)的影响。方法:将本院60例急性自发性脑出血患者随机分为对照组30例和治疗组30例,对照组采取常规治疗,治疗组在对照组的基础上口服瑞舒伐他汀,10mg/次,每晚服用1次,疗程为14d;分别于治疗前后测定两组患者的神经功能缺损程度评分(neurological deficiency score,NDS),血清MDA、IL-1β和TNF-α水平。结果:与对照组相比,治疗组NDS值、MDA、IL-1β及TNF-α水平均显著降低(P<0.05)。结论:瑞舒伐他汀可以降低急性自发性脑出血患者的血清MDA、IL-1β和TNF-α水平,提示该药可通过抑制氧化应激和炎症反应的途径发挥治疗作用。Objective：To explore the clinical efficacy and malondialdehyde （MDA）, interleukin -1β （IL-1β）,tumor necrosis factor （TNF-α）with rosuvastatin in patients with acute spontaneous intracerebral hemorrhage.Methods：Randomly dividing 60 patients with acute spontaneous intracerebral hemorrhage in our hospital into the control group of 30 cases and rosuvastatin treatment group of 30 cases, the control group were taked conventional therapy, the treatment group were treated with rosuvastatin on the basis of the conventional therapy, 10mg qn, treatment for 14 days, measured the two groups of patients with NDS, serum MDA, IL-1βand TNF-αbefore and after treatment.Result：Compared with the control group, the NDS, MDA, IL-1β and TNF-α of treatment group were significantly reduced （P〈0.05）.Conclusion：Rosuvastatin can reduce serum MDA, IL-1βand TNF-αof patients with acute spontaneous intracerebral hemorrhage, revealing that the drug may exert a therapeutic effect through the inhibition of oxidative stress and inflammatory response.

关 键 词：瑞舒伐他汀 急性自发性脑出血 氧自由基 炎症因子 

分 类 号：R743.34[医药卫生—神经病学与精神病学]